Verona Pharma to Present at 42nd Annual J.P. Morgan Healthcare Conference
January 03 2024 - 2:00AM
Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the
“Company”), announces that senior management will present a company
overview at the 42nd Annual J.P. Morgan Healthcare Conference on
Wednesday, January 10, 2024 at 4:30 PM PST / 12:30 AM GMT.
A webcast of the event will be available on the
Events and Presentations link on the Investors page of the
Company’s website, www.veronapharma.com.
For further information please contact:
Verona Pharma plc |
US Tel: +1-833-417-0262UK Tel: +44 (0)203 283 4200 |
Victoria Stewart, Senior Director of Investor Relations and
Communications |
IR@veronapharma.com |
Argot PartnersUS Investor Enquiries |
Tel: +1-212-600-1902verona@argotpartners.com |
Ten Bridge CommunicationsInternational / US Media
Enquiries |
Tel: +1-312-523-5016tbcverona@tenbridgecommunications.com |
Leslie Humbel |
|
About Verona Pharma
Verona Pharma is a clinical-stage
biopharmaceutical company focused on developing and commercializing
innovative therapies for the treatment of chronic respiratory
diseases with significant unmet medical needs. If successfully
developed and approved, Verona Pharma’s product candidate,
ensifentrine, has the potential to become the first non-steroidal
therapy for the treatment of respiratory diseases that combines
bronchodilator and anti-inflammatory activities in one molecule.
The Company has evaluated nebulized ensifentrine in its Phase 3
clinical program ENHANCE (“Ensifentrine as a Novel inHAled
Nebulized COPD thErapy”) for COPD maintenance treatment.
Ensifentrine met the primary endpoint in both ENHANCE-1 and
ENHANCE-2 trials demonstrating statistically significant and
clinically meaningful improvements in lung function. In addition,
ensifentrine substantially reduced the rate and risk of COPD
exacerbations in pooled analysis from ENHANCE-1 and ENHANCE-2. In
the third quarter of 2023, the US Food and Drug Administration
accepted for review the Company’s NDA for ensifentrine for the
maintenance treatment of patients with COPD and assigned a PDUFA
target action date of June 26, 2024. Two additional
formulations of ensifentrine have been evaluated in Phase 2 trials
for the treatment of COPD: dry powder inhaler (“DPI”) and
pressurized metered-dose inhaler (“pMDI”). Ensifentrine has
potential applications in cystic fibrosis, non-cystic fibrosis
bronchiectasis, asthma and other respiratory diseases. For more
information, please visit www.veronapharma.com.
Verona Pharma (NASDAQ:VRNA)
Historical Stock Chart
From Apr 2024 to May 2024
Verona Pharma (NASDAQ:VRNA)
Historical Stock Chart
From May 2023 to May 2024